Sigilon Therapeutics (SGTX) IPO Opens 22% Higher

Today's IPO for Sigilon Therapeutics Inc. (NASDAQ: SGTX) opened at $22 after pricing its upsized initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share.

In addition, Sigilon has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Morgan Stanley, Jefferies, Barclays and Canaccord Genuity are acting as joint book-running managers for the offering.

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Singularity Future Technology closes $1.8M registered direct offering
• BlockDAG’s $3M USDT End-of-Summer Raffle Closes Soon: BDAG at $0.00000007 Beats Hype Token & Dogecoin Forecasts